MicroQuin Secures DoD CDMRP Grant for Innovative Rare Cancer Treatment Development

Rare cancers affect thousands of patients worldwide, yet they often receive less attention and funding compared to more common cancers. This gap slows progress in developing effective treatments for these challenging diseases. MicroQuin, a biotechnology company focused on cancer therapies, has recently taken a significant step forward by securing a grant from the Department of Defense’s Congressionally Directed Medical Research Programs (DoD CDMRP). This funding will support MicroQuin’s efforts to develop new treatments targeting rare cancers, offering hope to patients and clinicians alike.

MicroQuin laboratory equipment for rare cancer research

Understanding the Importance of Rare Cancer Research

Rare cancers, by definition, affect fewer than 15 people per 100,000 annually. Despite their low incidence individually, collectively they represent about 20% of all cancer diagnoses. Patients with rare cancers often face limited treatment options because pharmaceutical companies prioritize more common cancers with larger markets. This leaves many rare cancer patients with therapies that are less effective or have significant side effects.

The DoD CDMRP grant awarded to MicroQuin recognizes the urgent need to address this disparity. The program funds research projects that show promise in improving outcomes for patients with rare and difficult-to-treat cancers. By supporting MicroQuin, the DoD CDMRP aims to accelerate the development of therapies that could fill critical gaps in cancer care.